Building Confidence With FGFR-Targeted Therapy in Practice: Case-Based Approaches in Optimizing Patient Outcomes in FGFR+ Bladder Cancer
Learning Objectives
- Identify who/when to test for FGFR alterations and interpret results to inform biomarker-driven treatment planning.
- Describe treatment sequencing, including where FGFR-targeted therapy may fit for eligible patients.
- Outline practical monitoring and adverse event management for FGFR inhibitors and apply best practices to integrate care into routine clinic workflows.
Why Attend?
As the role of FGFR-targeted therapy continues to evolve in the management of advanced urothelial carcinoma, staying current with emerging evidence and practical treatment strategies is essential. Join Canadian experts for an interactive, case-based webinar that will explore how to confidently identify patients with FGFR alterations, incorporate biomarker testing into clinical decision-making, and optimize treatment sequencing.
Through real-world patient cases and practical discussion, you’ll gain actionable insights into the effective use of FGFR inhibitors, including monitoring, adverse event management, and multidisciplinary approaches that can help improve patient outcomes and seamlessly integrate these therapies into everyday clinical practice.
Event Co-Chairs
Moderator / Speaker
Maria Jiang
MD, MSc, FRCPC
Dr. Maria Jiang is a GU medical oncologist at Princess Margaret Cancer Centre (PM) and an Assistant Professor at the University of Toronto. She completed her Medical Oncology Residency in Toronto, fellowship at PM, and Master of Science in Clinical Epidemiology at the Harvard T.H. Chan School of Public Health. Her research focuses on targeted therapies in GU malignancies.
Dr. Jiang has received multiple research grants, developed several investigator-initiated trials, and was awarded the Medical Oncology Training Program Outstanding Teaching Award. She serves as co-lead of the Theranostics Working Group at UHN and PM representative for the Canadian Cancer Trials Group.
Speaker
Nimira Alimohamed
MD, FRCPC
Dr. Alimohamed is a Medical Oncologist at the Arthur JE Child Comprehensive Cancer Centre, Calgary, AB as well as a Clinical Associate Professor in the Department of Medicine at the University of Calgary. She is the provincial GU tumour lead in Alberta.
Dr Alimohamed is actively involved in clinical trials in GU malignancies with specific research interests in bladder cancer. She is working to improve outcomes for patients with GU malignancies through real-world evidence collection, patient care pathways, and biomarker evaluation.
This session is part of a multi-channel educational series aimed at improving clinical confidence and patient care in the era of ALK inhibitor therapy
This program has been made possible through unrestricted support from Johnson & Johnson.
Register Now
All OncologyEducation programs are intended exclusively for healthcare professionals.